hOMSC 300
Alternative Names: hOMSC; hOMSC-300; human Oral Mucosa Stem CellsLatest Information Update: 09 Mar 2023
At a glance
- Originator CYTORA
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple system atrophy
Most Recent Events
- 02 Feb 2023 Cytora has patent protection for hOMSC technology platform worldwide (Cytora website, February 2023)
- 07 Nov 2022 Phase-I/II clinical trials in Multiple system atrophy in Israel (Intratracheal) (NCT05698017)